Navigation Links
Codexis Achieves Development Milestones With Teva

REDWOOD CITY, Calif., May 16, 2011 /PRNewswire/ -- Codexis, Inc. (Nasdaq: CDXS) today announced the continued expansion of its collaboration with Teva Pharmaceutical Industries Ltd., the world's largest generic drug manufacturer.  Codexis has now successfully completed technology transfer of custom biocatalysts for manufacture of three undisclosed pharmaceutical products to Teva.  Two products have been transferred to pilot manufacturing and a third to full scale commercial manufacturing.  The original agreements covering development of these processes were signed in 2009.  

Teva is using Codexis biocatalysis technology to reengineer key process steps in the manufacture of the covered generic products.  Codexis develops proprietary custom biocatalysts which can reduce pharmaceutical manufacturing development time and costs.  Codexis technology is used by leading drug and chemical companies worldwide.  Financial terms were not disclosed.

"These are significant achievements in our relationship with Teva," said Joseph Sarret, M.D., Senior Vice President and Chief Business Officer.  "We are developing custom biocatalytic manufacturing processes for four Teva products, and the transfer to pilot and commercial manufacturing is important recognition of the cost savings and value-added technology that Codexis brings to the highly competitive generics marketplace."

Codexis is a clean technology company. Codexis develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis’ technology is commercialized with leading global pharmaceutical companies and in development for advanced biofuels with Shell and carbon capture. Other potential markets for the company’s biocatalyst-enabled solutions include chemicals and water treatment.

Forward-Looking Statements

This press release contains forward-looking statements relating to Codexis development of biocatalysts for use in creating manufacturing processes for certain Teva products. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results. Factors that could materially affect actual results can be found in Codexis Quarterly Report on Form 10-Q dated May 6, 2011 including under the caption "Risk Factors." Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.


Media: Lyn Christenson,, 650-421-8144 or Saskia Sidenfaden,, 212-827-3771.  

Investors:  Henk Adriaenssens,, 650-421-8331

SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Codexis Names Fernando Valle Research Fellow
2. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
3. Codexis Expands Collaboration with Teva
4. Codexis Expands Pharmaceutical Manufacturing Partnerships
5. Codexis, Inc. Announces Pricing of Initial Public Offering
6. Codexis CEO Alan Shaw Named Ernst & Young Entrepreneur Of The Year® 2010 Recipient in Northern California
7. Codexis Names Peter Strumph SVP, Commercial Operations
8. Codexis to Present at the Pacific Crest Technology Leadership Forum
9. Codexis Expands Codex® Panel Product Family at CPhI
10. Codexis to Announce Third Quarter 2010 Financial Results October 28, 2010
11. Codexis to Present at Piper Conference
Post Your Comments:
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... ... 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... videos a whole new perspective by using the title layers in ProSlice Levels ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
Breaking Medicine News(10 mins):